 Paula Riggs
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 36 | 2023 | 971 | 5.070 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 18 | 2015 | 366 | 2.110 |
Why?
| | Marijuana Smoking | 5 | 2023 | 220 | 1.700 |
Why?
| | Central Nervous System Stimulants | 9 | 2013 | 142 | 1.520 |
Why?
| | Cannabis | 4 | 2023 | 382 | 1.300 |
Why?
| | Prescription Drug Misuse | 3 | 2019 | 38 | 1.280 |
Why?
| | Fluoxetine | 3 | 2019 | 47 | 1.120 |
Why?
| | Prescription Drugs | 2 | 2019 | 113 | 1.110 |
Why?
| | Conduct Disorder | 6 | 2012 | 191 | 0.990 |
Why?
| | Adolescent Behavior | 7 | 2016 | 482 | 0.970 |
Why?
| | Substance Abuse, Intravenous | 2 | 2016 | 80 | 0.970 |
Why?
| | Adolescent | 46 | 2023 | 18480 | 0.920 |
Why?
| | Opioid-Related Disorders | 3 | 2019 | 417 | 0.860 |
Why?
| | Escherichia coli | 10 | 2021 | 758 | 0.820 |
Why?
| | Problem Behavior | 1 | 2022 | 85 | 0.810 |
Why?
| | Hallucinogens | 1 | 2023 | 74 | 0.800 |
Why?
| | Methylphenidate | 6 | 2012 | 36 | 0.760 |
Why?
| | Mental Disorders | 6 | 2016 | 939 | 0.740 |
Why?
| | Maltose-Binding Proteins | 7 | 2021 | 10 | 0.730 |
Why?
| | Escherichia coli Proteins | 8 | 2021 | 170 | 0.720 |
Why?
| | Recombinant Fusion Proteins | 9 | 2021 | 653 | 0.720 |
Why?
| | Psychiatry | 1 | 2022 | 201 | 0.680 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 233 | 0.560 |
Why?
| | School Health Services | 2 | 2016 | 203 | 0.560 |
Why?
| | Depression | 2 | 2019 | 1132 | 0.560 |
Why?
| | Acetic Acid | 1 | 2015 | 17 | 0.540 |
Why?
| | Honey | 1 | 2015 | 8 | 0.530 |
Why?
| | Health Care Reform | 1 | 2016 | 95 | 0.530 |
Why?
| | Early Medical Intervention | 1 | 2016 | 56 | 0.530 |
Why?
| | Depressive Disorder, Major | 4 | 2011 | 303 | 0.490 |
Why?
| | Homeless Youth | 1 | 2013 | 15 | 0.480 |
Why?
| | Public Health | 2 | 2016 | 450 | 0.470 |
Why?
| | Academies and Institutes | 1 | 2013 | 44 | 0.470 |
Why?
| | Carrier Proteins | 6 | 2001 | 726 | 0.460 |
Why?
| | Awards and Prizes | 1 | 2013 | 57 | 0.450 |
Why?
| | Analgesics, Opioid | 2 | 2019 | 794 | 0.440 |
Why?
| | Humans | 53 | 2023 | 118972 | 0.420 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 693 | 0.420 |
Why?
| | Drug Overdose | 1 | 2016 | 294 | 0.420 |
Why?
| | Periodicals as Topic | 1 | 2013 | 191 | 0.390 |
Why?
| | Pemoline | 2 | 2004 | 5 | 0.390 |
Why?
| | Empirical Research | 1 | 2010 | 25 | 0.370 |
Why?
| | Research Subjects | 1 | 2010 | 40 | 0.370 |
Why?
| | Mutant Proteins | 1 | 2010 | 100 | 0.370 |
Why?
| | Psychology, Adolescent | 2 | 2007 | 63 | 0.340 |
Why?
| | Mutation, Missense | 1 | 2010 | 300 | 0.320 |
Why?
| | Diagnosis, Dual (Psychiatry) | 6 | 2015 | 36 | 0.320 |
Why?
| | Education, Continuing | 1 | 2008 | 40 | 0.310 |
Why?
| | Neurobiology | 1 | 2007 | 18 | 0.310 |
Why?
| | Mental Health | 2 | 2023 | 568 | 0.310 |
Why?
| | Drug Therapy | 1 | 2008 | 76 | 0.310 |
Why?
| | Family | 5 | 2022 | 585 | 0.290 |
Why?
| | Drug Prescriptions | 1 | 2008 | 248 | 0.270 |
Why?
| | Comorbidity | 8 | 2016 | 1527 | 0.270 |
Why?
| | Protein Engineering | 2 | 2010 | 107 | 0.260 |
Why?
| | Personality Disorders | 3 | 2006 | 68 | 0.260 |
Why?
| | Juvenile Delinquency | 4 | 2004 | 103 | 0.260 |
Why?
| | Protein Disulfide-Isomerases | 3 | 2015 | 10 | 0.250 |
Why?
| | Male | 31 | 2021 | 57801 | 0.250 |
Why?
| | Depressive Disorder | 3 | 1997 | 333 | 0.250 |
Why?
| | Research | 1 | 2007 | 411 | 0.240 |
Why?
| | Linear Models | 2 | 2018 | 827 | 0.240 |
Why?
| | Combined Modality Therapy | 6 | 2011 | 1166 | 0.230 |
Why?
| | Schizophrenia | 1 | 2008 | 501 | 0.220 |
Why?
| | Young Adult | 6 | 2019 | 10793 | 0.220 |
Why?
| | Tobacco Use Disorder | 3 | 2011 | 233 | 0.220 |
Why?
| | Protein Folding | 3 | 2015 | 250 | 0.220 |
Why?
| | Adolescent Health | 1 | 2022 | 39 | 0.220 |
Why?
| | Oxidoreductases | 2 | 2015 | 100 | 0.210 |
Why?
| | Mental Health Services | 1 | 2005 | 331 | 0.200 |
Why?
| | Female | 21 | 2017 | 61564 | 0.200 |
Why?
| | Adult | 13 | 2021 | 31512 | 0.190 |
Why?
| | Child | 7 | 2023 | 19129 | 0.190 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2021 | 765 | 0.190 |
Why?
| | Genetic Vectors | 6 | 2001 | 302 | 0.190 |
Why?
| | Prokaryotic Cells | 1 | 2019 | 5 | 0.180 |
Why?
| | Oxidation-Reduction | 3 | 2019 | 940 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2016 | 9342 | 0.180 |
Why?
| | Sex Factors | 5 | 2017 | 1781 | 0.180 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1185 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1200 | 0.170 |
Why?
| | Epitopes | 1 | 2021 | 443 | 0.170 |
Why?
| | Prescriptions | 1 | 2019 | 63 | 0.170 |
Why?
| | Bupropion | 1 | 1998 | 38 | 0.170 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2513 | 0.170 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 1998 | 53 | 0.160 |
Why?
| | Disulfides | 3 | 2015 | 91 | 0.160 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 17 | 0.160 |
Why?
| | Motivational Interviewing | 1 | 2019 | 84 | 0.160 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1998 | 56 | 0.160 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 395 | 0.150 |
Why?
| | Cytoplasm | 2 | 2015 | 269 | 0.150 |
Why?
| | Antisocial Personality Disorder | 1 | 1998 | 159 | 0.150 |
Why?
| | Clonidine | 1 | 1996 | 21 | 0.150 |
Why?
| | Bayes Theorem | 1 | 2018 | 344 | 0.140 |
Why?
| | Genes, Reporter | 1 | 1997 | 270 | 0.140 |
Why?
| | Chromatography, Affinity | 4 | 2001 | 85 | 0.140 |
Why?
| | Solubility | 2 | 2010 | 235 | 0.140 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2871 | 0.140 |
Why?
| | Organisms, Genetically Modified | 1 | 2015 | 18 | 0.140 |
Why?
| | Sulfenic Acids | 1 | 2015 | 7 | 0.140 |
Why?
| | Statistical Distributions | 1 | 2015 | 8 | 0.130 |
Why?
| | Chromatography, Ion Exchange | 3 | 2001 | 51 | 0.130 |
Why?
| | Problem Solving | 2 | 2006 | 145 | 0.130 |
Why?
| | Social Behavior Disorders | 1 | 1995 | 15 | 0.130 |
Why?
| | Antidepressive Agents | 1 | 1997 | 189 | 0.130 |
Why?
| | Psychotropic Drugs | 1 | 1995 | 58 | 0.130 |
Why?
| | Behavior, Addictive | 1 | 2015 | 77 | 0.120 |
Why?
| | Placebos | 2 | 2011 | 202 | 0.120 |
Why?
| | Risk Factors | 2 | 2023 | 9000 | 0.120 |
Why?
| | Antibody Formation | 1 | 2015 | 276 | 0.120 |
Why?
| | Delayed-Action Preparations | 2 | 2011 | 161 | 0.120 |
Why?
| | Risk | 1 | 2016 | 853 | 0.120 |
Why?
| | Cloning, Molecular | 5 | 2000 | 546 | 0.120 |
Why?
| | Interpersonal Relations | 2 | 2006 | 345 | 0.120 |
Why?
| | Smoking | 3 | 2011 | 1487 | 0.110 |
Why?
| | Models, Molecular | 3 | 2010 | 1435 | 0.110 |
Why?
| | Colorado | 4 | 2017 | 4196 | 0.100 |
Why?
| | Crystallography, X-Ray | 3 | 2021 | 422 | 0.100 |
Why?
| | Behavior Therapy | 3 | 2015 | 237 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2015 | 788 | 0.100 |
Why?
| | Models, Statistical | 1 | 2015 | 636 | 0.100 |
Why?
| | Protein Structure, Tertiary | 2 | 2010 | 823 | 0.100 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 403 | 0.100 |
Why?
| | Propylamines | 1 | 2010 | 12 | 0.090 |
Why?
| | DNA | 1 | 1997 | 1388 | 0.090 |
Why?
| | Alcoholic Beverages | 1 | 2010 | 17 | 0.090 |
Why?
| | Periplasmic Proteins | 1 | 2009 | 3 | 0.090 |
Why?
| | Bacteroides fragilis | 1 | 2009 | 11 | 0.090 |
Why?
| | Polysaccharides | 1 | 2010 | 78 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 499 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 276 | 0.090 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 338 | 0.090 |
Why?
| | Alcohol-Related Disorders | 2 | 2011 | 111 | 0.080 |
Why?
| | Epidemiologic Studies | 1 | 2008 | 58 | 0.080 |
Why?
| | Harm Reduction | 1 | 2007 | 25 | 0.080 |
Why?
| | Plasmids | 4 | 2015 | 355 | 0.070 |
Why?
| | Adaptation, Psychological | 1 | 2011 | 557 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2071 | 0.070 |
Why?
| | Base Sequence | 4 | 2000 | 2159 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 125 | 0.070 |
Why?
| | Kinetics | 1 | 2010 | 1624 | 0.070 |
Why?
| | Citalopram | 1 | 2006 | 27 | 0.070 |
Why?
| | Health Surveys | 1 | 2008 | 454 | 0.070 |
Why?
| | Marijuana Abuse | 2 | 2005 | 209 | 0.070 |
Why?
| | Mutation | 2 | 2015 | 3457 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 245 | 0.060 |
Why?
| | Patient Selection | 1 | 2009 | 676 | 0.060 |
Why?
| | Alcohol Drinking | 2 | 2015 | 652 | 0.060 |
Why?
| | Managed Care Programs | 1 | 2005 | 135 | 0.060 |
Why?
| | Pilot Projects | 2 | 2000 | 1419 | 0.060 |
Why?
| | Aged | 2 | 2016 | 19657 | 0.060 |
Why?
| | Middle Aged | 3 | 2016 | 27617 | 0.060 |
Why?
| | Motivation | 2 | 2010 | 506 | 0.060 |
Why?
| | Age of Onset | 1 | 2005 | 467 | 0.060 |
Why?
| | Narcotics | 1 | 2003 | 50 | 0.060 |
Why?
| | Research Design | 3 | 2018 | 969 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2008 | 699 | 0.060 |
Why?
| | Child Behavior | 1 | 2004 | 212 | 0.050 |
Why?
| | Child, Preschool | 1 | 1996 | 9491 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2012 | 2674 | 0.050 |
Why?
| | Osmosis | 2 | 2012 | 18 | 0.050 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1308 | 0.050 |
Why?
| | Safety | 1 | 2004 | 304 | 0.050 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 136 | 0.050 |
Why?
| | Alkaline Phosphatase | 2 | 2015 | 157 | 0.050 |
Why?
| | Periplasmic Binding Proteins | 1 | 2001 | 14 | 0.050 |
Why?
| | Periplasm | 1 | 2001 | 10 | 0.050 |
Why?
| | Health Promotion | 1 | 2007 | 691 | 0.050 |
Why?
| | Drug Compounding | 1 | 2021 | 90 | 0.050 |
Why?
| | Enteropeptidase | 1 | 2000 | 2 | 0.050 |
Why?
| | Amylose | 1 | 2000 | 4 | 0.050 |
Why?
| | Maltose | 1 | 2000 | 6 | 0.050 |
Why?
| | Factor Xa | 1 | 2000 | 31 | 0.050 |
Why?
| | Protein Denaturation | 1 | 2000 | 73 | 0.050 |
Why?
| | Durapatite | 1 | 2000 | 33 | 0.050 |
Why?
| | Parent-Child Relations | 3 | 2006 | 232 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 456 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 756 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2009 | 648 | 0.040 |
Why?
| | Personality Assessment | 2 | 1997 | 78 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2019 | 54 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2019 | 83 | 0.040 |
Why?
| | Monosaccharide Transport Proteins | 2 | 1988 | 46 | 0.040 |
Why?
| | Genes, Bacterial | 2 | 1989 | 162 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2001 | 408 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 355 | 0.040 |
Why?
| | Cohort Studies | 2 | 2005 | 5116 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2019 | 107 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 1988 | 125 | 0.040 |
Why?
| | Likelihood Functions | 1 | 2018 | 136 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2019 | 305 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2005 | 972 | 0.040 |
Why?
| | Magnesium | 1 | 1997 | 150 | 0.040 |
Why?
| | DNA, Recombinant | 1 | 1997 | 42 | 0.040 |
Why?
| | Substrate Specificity | 1 | 1997 | 371 | 0.040 |
Why?
| | Catalysis | 1 | 1997 | 295 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1997 | 363 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2008 | 6561 | 0.040 |
Why?
| | Prevalence | 2 | 2017 | 2326 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 129 | 0.030 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2015 | 12 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 1440 | 0.030 |
Why?
| | Glycosylation | 1 | 2015 | 129 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2015 | 85 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 332 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 975 | 0.030 |
Why?
| | Stochastic Processes | 1 | 2015 | 66 | 0.030 |
Why?
| | Personality Inventory | 1 | 1995 | 134 | 0.030 |
Why?
| | Copper | 1 | 2015 | 102 | 0.030 |
Why?
| | Psychotherapy | 2 | 2006 | 177 | 0.030 |
Why?
| | Protein Conformation | 1 | 1997 | 848 | 0.030 |
Why?
| | Bacteriophages | 1 | 2015 | 76 | 0.030 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2009 | 42 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 412 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 922 | 0.030 |
Why?
| | Alcoholism | 1 | 2000 | 717 | 0.030 |
Why?
| | Patient Care Team | 1 | 1998 | 521 | 0.030 |
Why?
| | Bacterial Proteins | 2 | 1989 | 759 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 392 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 827 | 0.030 |
Why?
| | HIV Infections | 1 | 2007 | 2459 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2019 | 1178 | 0.030 |
Why?
| | Mandatory Programs | 1 | 2012 | 16 | 0.030 |
Why?
| | Genetic Testing | 1 | 2015 | 389 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1194 | 0.030 |
Why?
| | Membrane Proteins | 2 | 1989 | 1055 | 0.030 |
Why?
| | Patient Compliance | 1 | 1996 | 537 | 0.030 |
Why?
| | Thioredoxins | 1 | 2012 | 30 | 0.030 |
Why?
| | Ethanol | 1 | 1997 | 575 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 1996 | 610 | 0.030 |
Why?
| | Risk-Taking | 1 | 2015 | 319 | 0.030 |
Why?
| | Age Factors | 1 | 1999 | 2995 | 0.030 |
Why?
| | Amino Acids | 1 | 2015 | 464 | 0.030 |
Why?
| | United States | 1 | 2008 | 12555 | 0.020 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2010 | 4 | 0.020 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2010 | 13 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2010 | 93 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2009 | 62 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 306 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 81 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 622 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 239 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1323 | 0.020 |
Why?
| | Community Mental Health Centers | 1 | 2009 | 14 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 361 | 0.020 |
Why?
| | Social Work | 1 | 2009 | 69 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2009 | 253 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1687 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 969 | 0.020 |
Why?
| | Smoking Prevention | 1 | 2004 | 150 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 362 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 351 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2490 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2007 | 482 | 0.010 |
Why?
| | Counseling | 1 | 2006 | 353 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1244 | 0.010 |
Why?
| | Models, Biological | 1 | 2009 | 1715 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1996 | 57 | 0.010 |
Why?
| | Sampling Studies | 1 | 1996 | 92 | 0.010 |
Why?
| | RNA Probes | 1 | 1995 | 14 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1995 | 67 | 0.010 |
Why?
| | Intelligence | 1 | 1996 | 136 | 0.010 |
Why?
| | Mood Disorders | 1 | 1996 | 119 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1996 | 525 | 0.010 |
Why?
| | Aggression | 1 | 1996 | 183 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6412 | 0.010 |
Why?
| | Genotype | 2 | 1989 | 1882 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1996 | 1293 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4708 | 0.010 |
Why?
| | Incidence | 1 | 1997 | 2424 | 0.010 |
Why?
| | Transformation, Bacterial | 1 | 1989 | 5 | 0.010 |
Why?
| | SEC Translocation Channels | 1 | 1989 | 10 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1989 | 76 | 0.010 |
Why?
| | Lac Operon | 1 | 1989 | 47 | 0.010 |
Why?
| | DNA Restriction Enzymes | 1 | 1988 | 53 | 0.010 |
Why?
| | Genes | 1 | 1988 | 231 | 0.000 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 4552 | 0.000 |
Why?
|
|
Riggs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|